VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer

Vemurafenib, an inhibitor of mutant BRAF activity, is a promising anticancer agent for patients with BRAF-mutant metastatic melanoma. However, it is less effective in BRAF-mutant thyroid cancer, and the reason for this discrepancy is not yet fully elucidated. By RNA sequencing analysis, we identifie...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transl Oncol
Autors principals: Chen, Shitu, Su, Xingyun, Jiang, Xiaoxia, Zhang, Tuo, Min, Irene, Ding, Yongfeng, Wang, Xumeng, Mao, Zhuochao, Cao, Jiang, Teng, Xiaodong, Fahey, Thomas J., Wang, Weibin, Teng, Lisong
Format: Artigo
Idioma:Inglês
Publicat: Neoplasia Press 2020
Matèries:
Original article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6948368/
https://ncbi.nlm.nih.gov/pubmed/31911278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.10.007
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars